Medindia

X

Kamar Aulakh Joins Velos, Inc. as Chief Operating Officer

Thursday, March 18, 2010 Press Release J E 4
Advertisement


FREMONT, Calif., March 18 Velos, Inc., the recognized leader and trusted resource for clinical trials management information systems, announced today that Kamar Aulakh has joined the company to serve as Chief Operating Officer. Aulakh comes with an extensive background as engineer, entrepreneur and business leader in technology and healthcare. In his role as COO, he will oversee all operating teams to drive continued expansion and market leadership.

"We are very pleased to welcome a person of this caliber on board," said John S. McIlwain, President and CEO of Velos. "We're gratified to have the talents and accomplishments of Kamar Aulakh focused in Velos on a variety of levels. In its current stage of evolution Velos needs, and will benefit from, his considerable expertise and business acumen. He is already addressing issues of organizational readiness for growth and structural improvements throughout all our operations."

Aulakh has substantial corporate experience. He was President and CEO of Quark, Inc., a leading developer of software solutions for professional publishers worldwide. During his tenure, he grew Quark to a 1900-employee organization positioned to take advantage of the next major shift in publishing, that of end-to-end digital workflows and multi-channel output. He established and managed technology development centers in the U.S., Germany, Singapore and India. Prior to that, he held various senior management and technical positions with Fortune 500 Companies working in telecommunications, energy and healthcare sectors.

As entrepreneur, Aulakh founded companies in the U.S., Switzerland and India. These include: NexOkO, providing customers with an Internet-based subscription service for managing their digital content and communications; PioneeringMed, employing innovative techniques to automate and improve healthcare processes; and BayaTree, a forward-thinking business consulting company with a focus on project management, business processes, outsourcing and technology enabled services.

"Velos customers receive more than 40% of NIH extramural grants and 50% are among the 100 biggest such recipients. These are the largest market shares in our product class. We continue to expand both in the U.S. and globally," said McIlwain. "Kamar Aulakh's proven know-how in all facets of software and Internet operations will be very valuable as we go forward. We're proud that he has decided to accept the challenge with us."

About Velos

Velos, Inc. is the trusted clinical trial management resource for investigators, sponsors and academic leaders throughout the U.S. Its customers include 21 of the top 25 academic medical centers and research institutions. Among the 100 largest recipients of NIH clinical research funding, Velos customers receive over 50% of NIH extramural grants. Velos eResearch is deployed for clinical research in all parts of the healthcare enterprise and supports a broad diversity of clinical departments and functional needs. The system fundamentally improves the way data is collected, organized and shared. A pure Internet technology platform, Velos eResearch harnesses advanced powers of the Internet to enable research sites, sponsors, and patients to collaborate in a secure, integrated system platform. System users are freed of redundant data entry and related time delays associated with most clinical research today. With emphasis on workflow, Velos integrates the clinical, administrative and financial information needs of research management. Velos eResearch has been certified as caBIGŪ Bronze Compatible by the caBIGŪ Bronze Compatibility Certification Program, created by the National Cancer Institute Center for Bioinformatics, in cooperation with the NCI Technology Transfer Branch. Founded in 1996, Velos is privately held with headquarters in Fremont, California. For more information, visit www.velos.com

This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements.

SOURCE Velos, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Access MediQuip Announces Release of the Country's...
S
Kendle Executive to Share Insights at World Pharma...